ASCO® 2023 Insights: "Dose Expansion Results of the Bifunctional EGFR/TGFβ Inhibitor BCA101 + Pembro in Pts With Recurrent, mHNSCC"
By
Dana-Farber Cancer Institute
FEATURING
Glenn Hanna
By
Dana-Farber Cancer Institute
FEATURING
Glenn Hanna
Login to view comments.
Click here to Login